Free Word download • Edit online • Save & share with Drive • Export to PDF
An Innovation Ideas for Your Product and Technology agreement is a legally binding document that governs the formal submission, evaluation, and ownership of new product concepts or technical innovations exchanged between a company and an individual contributor — whether an employee, independent inventor, external startup, or innovation consultant. It establishes the precise scope of the idea being shared, assigns or preserves intellectual property rights, imposes confidentiality obligations on the receiving company, sets a defined evaluation window, and specifies what compensation the submitter receives if the idea is commercialized. Unlike a standard NDA, this agreement addresses the full lifecycle of an innovation submission — from first disclosure through commercialization or reversion — in a single enforceable instrument.
Without a signed innovation ideas agreement in place before any disclosure, both parties face serious and largely avoidable legal exposure. A company that evaluates an unsolicited idea without a formal submission agreement may later face claims that it misappropriated the concept — even if it independently developed a similar product. An inventor who discloses a novel technology concept without this agreement in place has no contractual right to compensation, no guaranteed reversion of rights if the company declines, and no confidentiality obligations protecting the idea from being shared internally or acted upon without a deal. The consequences range from protracted IP litigation to the permanent loss of patent rights if the unprotected disclosure triggers a statutory public disclosure bar. This template gives both parties a clear, proportionate framework — evaluation rights for the company, IP protection and compensation rights for the submitter — closing the gaps that turn promising innovation partnerships into expensive disputes.
| If your situation is… | Use this template |
|---|---|
| Employee submitting an innovation idea through an internal company program | Innovation Ideas for Your Product and Technology |
| External inventor or startup sharing a concept with a corporate partner | Non-Disclosure Agreement (NDA) |
| Company licensing a patented technology from an external party | Technology License Agreement |
| Engaging a contractor to develop a new product or software feature | Independent Contractor Agreement |
| Joint development of a product between two companies | Joint Venture Agreement |
| Assigning all IP from a completed innovation project to the company | Intellectual Property Assignment Agreement |
| Compensating an inventor with royalties on commercialized innovations | Royalty Agreement |
Why it matters: Once an idea is disclosed without a signed agreement, confidentiality obligations are difficult to establish retroactively and any IP assignment may be challenged as lacking proper consideration.
Fix: Execute the agreement and obtain both signatures before sharing any written materials, diagrams, or verbal descriptions of the innovation.
Why it matters: Without a specific written description of the submitted idea attached to the agreement, the scope of what was assigned or protected is entirely disputed — courts cannot enforce obligations over an undefined subject matter.
Fix: Always attach a dated written description of the innovation, signed by both parties, as an exhibit incorporated by reference into the agreement.
Why it matters: An agreement to agree on material terms is generally unenforceable in common-law jurisdictions, leaving the submitter with no right to payment even if the company commercializes the idea successfully.
Fix: Include at minimum a royalty formula with a floor payment, a fixed lump sum, or a binding term that triggers negotiation within a specified deadline with a default mechanism if no deal is reached.
Why it matters: Courts in the US, UK, and EU frequently refuse to enforce perpetual confidentiality clauses as unreasonably restrictive, sometimes voiding the confidentiality section entirely rather than substituting a reasonable term.
Fix: Set a defined confidentiality period — typically 3 to 5 years — that is commercially reasonable and proportionate to the sensitivity of the information.
Why it matters: Without a reversion clause, an idea submitted to a company that never responds sits in legal limbo — the submitter cannot take it to a competitor and the company has no obligation to act.
Fix: Include an automatic reversion provision: if the company does not provide written notice of intent within the evaluation period, all rights revert to the submitter by operation of the agreement.
Why it matters: If the submitter is employed elsewhere or previously assigned IP rights to a university or prior employer, the company may acquire an idea it cannot legally use — triggering third-party infringement claims.
Fix: Require the submitter to warrant in writing that the idea is free of prior assignments and have them list any prior employers or institutions that may have claims before execution.
In plain language: Precisely identifies the innovation being submitted, distinguishes it from background IP the submitter already owns, and sets the boundaries of what the agreement covers.
'Innovation' means the concept, design, or technology described in Exhibit A, submitted by [SUBMITTER NAME] to [COMPANY NAME] on [DATE], and excludes any prior inventions listed in Exhibit B.
Common mistake: Leaving the definition of the submitted idea vague or oral — without an attached written description, both parties dispute what was actually disclosed, making ownership and evaluation disputes nearly impossible to resolve.
In plain language: Requires the receiving company to keep the submitted idea confidential for a defined period and to use it only for the purpose of evaluation, not to exploit it independently.
[COMPANY NAME] agrees to hold the Innovation in strict confidence for [X] years and to use the Innovation solely to evaluate its commercial potential, disclosing it only to employees with a need to know who are bound by equivalent obligations.
Common mistake: Setting no expiration on confidentiality obligations. Perpetual confidentiality clauses are unenforceable in several jurisdictions and courts may void the entire provision rather than impose a reasonable limit.
In plain language: Determines who owns the submitted idea and any derivatives — either confirming the submitter retains ownership pending a commercialization deal, or assigning ownership to the company upon signing or payment.
All right, title, and interest in the Innovation, including all patent, copyright, trade secret, and other intellectual property rights, are hereby assigned by [SUBMITTER NAME] to [COMPANY NAME] effective upon payment of [CONSIDERATION] as set out in Section [X].
Common mistake: Using ambiguous language like 'the company may use the idea' without specifying whether ownership transfers or a license is granted — creating a dispute about the scope of rights every time the company tries to commercialize.
In plain language: Grants the company a defined window to assess the idea's commercial viability and specifies what happens if no decision is made within that window — typically the idea reverts to the submitter.
[COMPANY NAME] shall have [60] days from the date of submission ('Evaluation Period') to assess the Innovation. If [COMPANY NAME] does not provide written notice of intent to license or acquire within the Evaluation Period, all rights revert to [SUBMITTER NAME] and the confidentiality obligations of Section [X] continue for [Y] years.
Common mistake: No reversion clause if the company fails to act. Without one, the submitter has no legal mechanism to reclaim rights or take the idea to another party after the evaluation stalls indefinitely.
In plain language: Sets out what the submitter receives in exchange for the idea — a lump-sum payment, royalty on commercialized revenue, equity, or a combination — and the conditions under which payment is triggered.
In consideration of the assignment, [COMPANY NAME] shall pay [SUBMITTER NAME] a royalty of [X]% of net revenue derived from products incorporating the Innovation, payable quarterly within [30] days of each quarter-end, for a period of [Y] years.
Common mistake: Leaving compensation terms entirely to a future negotiation without any formula or floor. Courts generally will not imply a reasonable compensation term, leaving the submitter with no enforceable right to payment.
In plain language: Requires the submitter to confirm that the idea is original, that they have the right to disclose and assign it, and that it does not infringe third-party IP rights.
[SUBMITTER NAME] represents and warrants that: (a) the Innovation is original and does not infringe any third-party patent, copyright, or trade secret; (b) [SUBMITTER NAME] is the sole inventor and has full authority to assign the Innovation; and (c) the Innovation is not subject to any prior assignment, license, or encumbrance.
Common mistake: Omitting a warranty on prior encumbrances. An idea already assigned to a previous employer or subject to a university IP policy creates immediate ownership conflicts that the receiving company cannot unwind without litigation.
In plain language: Prevents the receiving company from using information gained during the evaluation to bypass the submitter and independently develop, license, or exploit the idea or the submitter's contacts.
[COMPANY NAME] agrees not to circumvent [SUBMITTER NAME] by directly contacting, negotiating with, or entering into agreements with any third party identified in the submission documents for the purpose of developing or commercializing the Innovation, for a period of [X] years.
Common mistake: Using a non-circumvention clause so broad it effectively prevents the company from operating in its own industry. Courts routinely strike down overbroad non-circumvention terms, voiding the protection entirely.
In plain language: Caps the maximum liability of each party for breach of the agreement, typically excluding indirect damages such as lost profits and capping direct damages at amounts paid or a fixed ceiling.
In no event shall either party be liable for indirect, incidental, consequential, or punitive damages. Each party's total liability under this Agreement shall not exceed [the greater of $[X] or the amounts paid by [COMPANY NAME] in the [12] months preceding the claim].
Common mistake: No limitation of liability at all — exposing the receiving company to speculative lost-profits claims from a submitter who argues the innovation would have generated millions in unrealized revenue.
In plain language: Specifies which jurisdiction's law governs the agreement and the process for resolving disputes — typically negotiation, then mediation, then binding arbitration or litigation.
This Agreement is governed by the laws of [STATE / PROVINCE / COUNTRY]. Any dispute not resolved by good-faith negotiation within [30] days shall be submitted to binding arbitration administered by [AAA / JAMS / ICDR] in [CITY], except that either party may seek injunctive relief in a court of competent jurisdiction.
Common mistake: Choosing a governing law with no connection to either party's location or operations. Several jurisdictions — particularly California for IP matters — apply local law regardless of what the contract specifies.
Enter the full legal name of the submitter (individual or entity) and the receiving company, including their registered addresses and, where applicable, entity type and jurisdiction of incorporation.
💡 If the submitter is an employee, confirm their employment agreement doesn't already assign all innovations to the employer — this agreement may be redundant or contradictory.
Draft a clear, specific written description of the idea — including diagrams, specifications, or prototypes if available — and attach it as Exhibit A. The agreement's scope is limited to what is described in this exhibit.
💡 Date and sign the exhibit separately to create an independent record of what was disclosed and when, which matters if a patent dispute arises later.
Have the submitter list any pre-existing inventions, patents, or IP they are specifically excluding from the assignment so there is no ambiguity about what is transferred.
💡 An empty Exhibit B is a red flag — most experienced inventors have at least some prior work. Confirm the submitter has genuinely considered what to exclude.
Enter a specific number of days (typically 30–90) for the evaluation window and confirm what happens if no decision is made — rights revert to the submitter, confidentiality continues, or the parties negotiate an extension.
💡 60 days is the most common evaluation window for product ideas; 90 days is standard for complex technology with patent implications.
Choose between full assignment with a lump sum, a royalty-based license, an equity arrangement, or a deferred payment tied to commercialization milestones. State the formula and payment timeline explicitly.
💡 If you cannot agree on a fixed price, use a royalty formula with a minimum floor payment — it aligns incentives and avoids the 'future negotiation' trap.
Limit the non-circumvention clause to the specific contacts and industry segment identified in the submission. An overbroad clause covering the company's entire industry will likely be struck down by a court.
💡 Name the specific third parties, if any, that the non-circumvention covers rather than using a general prohibition — this makes the clause easier to enforce.
Confirm that the IP assignment and work-made-for-hire language complies with the law of the submitter's and company's jurisdiction — particularly for moral rights in Canada, the UK, and the EU.
💡 In Canada and the EU, moral rights cannot be assigned — add a waiver clause instead, which is permitted in most provinces and member states.
Both parties must execute the agreement before any substantive information about the innovation is shared. Post-disclosure signatures significantly weaken confidentiality and IP protections.
💡 Use a timestamped e-signature platform to create a clear record that execution preceded disclosure — this is critical evidence in any subsequent IP dispute.
An innovation ideas agreement for product and technology is a legally binding document that governs the terms under which a person submits a new product concept or technical idea to a company for evaluation. It establishes who owns the idea, how it will be kept confidential, what the submitter will receive if the company commercializes it, and how disputes will be resolved. Without this agreement in place before disclosure, both ownership and compensation become contested after the fact.
Both the submitter — whether an employee, independent inventor, contractor, or external startup — and an authorized representative of the receiving company must sign. For employee submissions, confirm whether the employment contract already covers innovation assignment; if it does, this agreement supplements or supersedes those terms depending on how it is drafted. Both signatures should be obtained before any substantive disclosure.
It depends on how the ownership clause is drafted. The agreement can be structured to assign full ownership to the company upon signing or payment, to grant a limited license for evaluation purposes only with ownership retained by the submitter, or to defer ownership transfer until a separate commercialization agreement is executed. Choose the structure that reflects the actual commercial arrangement before signing.
No, though it includes confidentiality obligations similar to an NDA. A standard NDA protects information from disclosure but does not address IP ownership, evaluation rights, compensation, or non-circumvention. An innovation ideas agreement covers all of these dimensions and is specifically designed for the submission and evaluation context. In many situations, both documents are used together.
A well-drafted agreement includes a reversion clause specifying that if the company does not provide written notice of intent within the evaluation period, all rights revert to the submitter automatically. Confidentiality obligations typically continue for a defined period after reversion — commonly 3 to 5 years — so the submitter can pursue other partners while the idea remains protected.
Possibly, but with significant complexity. Most employment contracts assign IP created by employees in connection with the employer's business, regardless of when or where it was developed. Several US states — including California, Delaware, and Illinois — have statutes limiting employer IP claims to work performed within the scope of employment. Employees should review their employment agreement and, if necessary, obtain a written carve-out before submitting the idea under this agreement.
The written description attached as Exhibit A should identify the problem the innovation solves, describe the solution in enough technical detail for a qualified reader to understand it, note the stage of development (concept, prototype, or market-ready), list any related patents or prior art the submitter is aware of, and state any specific claims of novelty. A vague description weakens both the IP assignment and the confidentiality scope — be as specific as the parties are comfortable disclosing at this stage.
No, a patent is not required before submission, but having a patent application on file strengthens the submitter's position considerably. A patent application creates a priority date that establishes when the invention was first claimed, which is critical in a later ownership dispute. If the idea has genuine commercial value, consider filing a provisional patent application — which costs relatively little — before disclosing to any company under this agreement.
Notarization is not required for this type of agreement to be enforceable in most jurisdictions. Both parties' signatures, obtained before disclosure, are generally sufficient. However, a notarized or witnessed copy may be useful if the idea has significant commercial value and a patent dispute is anticipated — the additional formality creates a stronger evidentiary record.
An NDA protects confidential information from unauthorized disclosure but does not address who owns the idea, what the submitter will be paid, how long the company has to evaluate, or what happens if no deal is reached. An innovation ideas agreement covers all of these dimensions. Use an NDA for general information sharing; use this agreement specifically when an idea is being formally submitted for commercial evaluation.
An IP assignment agreement transfers ownership of already-developed IP from one party to another — typically after a project is complete. An innovation ideas agreement governs the submission and evaluation process before any ownership decision is made. The innovation agreement often triggers an IP assignment as a later step once the company decides to proceed.
An independent contractor agreement governs the ongoing delivery of services and typically includes IP assignment for work product created during the engagement. An innovation ideas agreement covers a discrete one-time submission of a pre-existing idea, not work being performed under contract. If you are commissioning the development of a new idea rather than receiving a pre-existing one, a contractor agreement is the right starting point.
A joint venture agreement structures a shared business enterprise where both parties contribute resources and share risk and reward on an ongoing basis. An innovation ideas agreement is a narrower, transactional document covering a single submission and its evaluation. If the evaluation leads to a co-development arrangement, a joint venture or co-development agreement would typically follow as a separate instrument.
Algorithm, software feature, and platform innovation submissions require precise scope definitions and IP assignment language covering both code and underlying technical methods.
Product design improvements, materials innovations, and process efficiencies often have immediate patentability implications, making the evaluation timeline and prior-art warranty particularly critical.
External inventors frequently pitch product concepts to consumer brands; a formal submission agreement protects the brand from unsolicited-idea liability and the inventor from having the concept commercialized without compensation.
Medical device and drug delivery innovations involve regulatory IP considerations, potential FDA filings, and clinical data ownership that require jurisdiction-specific provisions beyond standard assignment language.
Algorithmic trading methods, payment processing innovations, and data analytics concepts often intersect with existing patent thickets and require careful prior-art representation from the submitter.
Renewable energy and efficiency technology submissions frequently involve government grant conditions or university spin-out obligations that the submitter must warrant are disclosed and resolved before assignment.
IP assignment is generally enforceable for employment-scope inventions under federal patent law. California, Delaware, Illinois, Minnesota, North Carolina, and Washington have statutes limiting employer IP claims to work performed within the employment scope, and requiring employees to be told about these limits. Work-made-for-hire doctrine under the Copyright Act applies to certain commissioned works but not to patents — patent assignment must be express and in writing.
Moral rights in Canada cannot be assigned under the Copyright Act but can be waived — include a moral rights waiver clause for any innovation with creative or software components. Provincial employment standards vary on IP assignment; Quebec's civil law framework differs from common-law provinces in how IP obligations are implied. University and government-funded research may be subject to institutional IP policies that the submitter must warrant are satisfied.
The Patents Act 1977 (sections 39–42) gives employees certain rights to compensation for inventions of outstanding benefit to the employer, even after assignment — these statutory rights cannot be contracted out. Moral rights under the Copyright, Designs and Patents Act 1988 persist post-assignment and must be explicitly waived in writing. Post-Brexit, the UK follows its own IP regime independently of the EU, though substantive rules remain broadly similar.
EU member states each have national patent and copyright laws that implement minimum harmonized standards; specific rules on employee invention compensation vary — Germany and France, for example, require employers to pay separate statutory compensation to employee inventors even where an assignment clause exists. Moral rights are recognized across all member states and are generally inalienable, though contractual waivers are permitted in some jurisdictions. GDPR applies to any personal data of the submitter processed during evaluation.
| Path | Best for | Cost | Time |
|---|---|---|---|
| Use the template | Internal employee innovation programs, low-stakes idea submissions, and early-stage ideation where the idea has not yet been prototyped or patented | Free | 30–45 minutes |
| Template + legal review | External inventor submissions, ideas with patent potential, or submissions involving equity or royalty compensation above $10,000 | $400–$900 for a 1–2 hour IP attorney review | 2–5 days |
| Custom drafted | High-value technology submissions, cross-border arrangements involving multiple jurisdictions, or situations where the submitter already has a patent application on file | $2,000–$6,000+ | 1–3 weeks |
This document is one of 3,000+ business & legal templates included in Business in a Box.
Access over 3,000+ business and legal templates for any business task, project or initiative.
Customize your ready-made business document template and save it in the cloud.
Share your files and folders with your team. Create a space of seamless collaboration.
"Fantastic value! I'm not sure how I'd do without it. It's worth its weight in gold and paid back for itself many times."
"I have been using Business in a Box for years. It has been the most useful source of templates I have encountered. I recommend it to anyone."
"It has been a life saver so many times I have lost count. Business in a Box has saved me so much time and as you know, time is money."
Stop downloading documents. Start operating with clarity. Business in a Box gives you the Business Operating System used by over 250,000 companies worldwide to structure, run, and grow their business.
Start free · No credit card required
